Rockland Trust Co. Lowers Position in Danaher Co. (NYSE:DHR)

Rockland Trust Co. reduced its position in shares of Danaher Co. (NYSE:DHR) by 44.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,452 shares of the conglomerate’s stock after selling 7,687 shares during the period. Rockland Trust Co.’s holdings in Danaher were worth $2,170,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Teachers Insurance & Annuity Association of America purchased a new position in shares of Danaher during the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. acquired a new position in Danaher during the third quarter worth $40,000. FSA Wealth Management LLC purchased a new position in Danaher in the third quarter worth $50,000. Darwin Wealth Management LLC acquired a new stake in Danaher in the third quarter valued at $55,000. Finally, Modus Advisors LLC purchased a new stake in shares of Danaher during the 4th quarter worth $56,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of several recent analyst reports. Stephens reiterated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. UBS Group reduced their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Stifel Nicolaus upped their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird reduced their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, Evercore ISI upped their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Stock Down 1.0 %

Shares of NYSE DHR opened at $237.58 on Wednesday. The firm’s 50 day moving average price is $235.27 and its 200 day moving average price is $253.56. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm has a market cap of $171.60 billion, a P/E ratio of 45.34, a price-to-earnings-growth ratio of 4.32 and a beta of 0.83. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 earnings per share. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s payout ratio is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.